• OFID 2018:5 (Suppl 1) • Poster Abstracts 9%) or coverage by the state's ADAP program (13% vs. 2%; P < 0.001 for insurance differences); "true" vs. "virtual" LTC patients more often received Ryan White case management services (69% vs. 15%, P < 0.001). More "virtual" vs. "true" LTC patients have subsequently returned to care (47% vs. 33%, P = 0.03). Active insurance most strongly associated with subsequent return to care on logistic regression.
Key Factors for Treatment Changes Within 1 Year After Starting ART in the
Background. Initiation of combined antiretroviral therapy (cART) has markedly increased survival and quality of life in HIV-infected patients. With the advent of new treatment options, including an increasing number of single-tablets, the durability of first-line ART regimes is developing.
Methods. We used data from the prospective multicenter German Clinical Surveillance of HIV Disease (ClinSurv) cohort of the Robert-Koch-Institute. Time to event was calculated as time between initiation of first-line cART and therapy change. We used a Cox model to assess predictors of treatment change 1 year after starting cART.
Results. We included 6,894 patients who initiated ART between 2005 and 2014. The sample population was predominantly men (79%) with German origin (69.8%), of which 49.6% were reporting sex with men (MSM) as main risk factor. Median age (IQR) was 38 (31-46) years. The most frequently treatment combinations were 2NRTI/PIr (48.1%) and 2NRTI/1NNRTI (42.2%), 2NRTI/1II (5.2%). 22.6% patients changed their first-line treatment within 1 year. Median (IQR) length between first intake and stop of the regime was 105 (35-214) days, which did not change significantly between 2005 (108; 38-217) and 2014 (128; 74-200) (P = 0.28). Most common documented causes were side effects of drugs 418 (44.0%) and non-adherence 173 (18.2%). In the Cox model (Figure 1 ), we identified numerous covariates associated with discontinuation of the first-line regime. A 2NRTI/1NNRTI regime was associated with higher rates (hazard ratio [HR] 1.28, 95% CI 1.06-1.55) and a 2NRTI/1II regime with lower rates (HR 0.34, 95% CI 0.23-0.51) of treatment modification (ref.: 2NRTI/1PIr). The HR increased markedly with the amount of daily-administered tablets from HR 2.15, 95% CI 1.48-3.11 (2-3 tablets) to HR 3.98, 95% CI 2.16-7.31 (10 tablets) (ref.: one tablet). We observed an association with a baseline viral load (VL) of >100 copies/mL (HR 0.65, 95% CI 0.53-0.81) and >100.000 copies/ mL (HR 0.68, 95% CI 0.54-0.85) (ref.: VL > 1 Mio. copies/mL).
Conclusion. Our analysis revealed, that side effects of drugs, the number of tablets per day and the VL at baseline are significantly associated with treatment change within the first year. A first-line regime with 2NRTI/1II seems to improve the adherence to the initial regime significantly.
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Do Comorbidities and Polypharmacy Lead to Virologic Failure in All Populations Living with HIV?
Humberto Jimenez, PharmD, BCPS, AAHIVP Background. As HIV antiretroviral therapy (ART) becomes increasingly more simplified and effective, many patients living with HIV benefit with reduced ART pill burden and longer life expectancy. As this patient population ages, the prevalence of comorbidities increases the likelihood of polypharmacy. This study assessed if comorbidities and their associated polypharmacy affect the success of HIV management in our patients.
Methods. A retrospective analysis of patients living with HIV receiving care at an urban clinic in New Jersey was performed. Eligible patients were ≥18 years old, had ≥2 visits in 2017 with laboratory data ≥24 weeks apart. These patients were divided into three arms: those without any comorbid conditions, a single comorbidity, and patients with multiple comorbidities. The primary endpoints were to determine the effect of comorbid conditions and polypharmacy on viral suppression (defined as HIV RNA <20 copies/mL). Secondary assessments accounted for the impact of age and race/ethnicity on HIV management.
Results. There were 318 patients included in the analysis: 156 with multiple comorbidities, 76 with one, and 86 without any. Most patients were male (58%) and the mean age was 49 years old. The population was 52% Black, 32% Hispanic, and 15% White. Most patients (72%) had undetectable virus, and 92% had a CD4 count >200 cells/mm 3 . Patients with multiple comorbidities were more likely to be virologically suppressed than patients with one comorbidity (80% vs. 59%, P = 0.0014) and those without (80% vs. 67%, P = 0.0413), despite having a higher pill burden per day (7.0 vs. 3.7 vs. 2.2, P = 0.0001). Although age was not an independent predictor of viral suppression, patients with multiple comorbidities were older (55 yo) than those with one comorbidity (48 yo) and without any (41 yo) (both P < 0.0001). Hypertension (39%), diabetes mellitus (16%), dyslipidemia (31%), and psychiatric disorders (14%) were the most common comorbidities. Patients with hypertension were more likely to be virologically suppressed than those without (80% vs. 67%, P = 0.0229).
Conclusion. Patients with multiple comorbidities and a greater daily pill burden at our clinic were more likely to achieve virologic suppression. Multiple comorbidities and polypharmacy were not major drivers of virologic failure in our clinic cohort.
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